As a key negative regulator of the type I interferon pathway, miR-146a is an attractive therapeutic target in SLE53, in part due to its activity in targeting SLE risk genes within or upstream of the type I interferon signaling pathway, such as IRF5, TRAF6, IRAK1, and STAT132,50. This evidence concerns the gene IRAK1 and systemic lupus erythematosus.